We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Aratana Therapeutics, Inc. (NASDAQGM: PETX) to Elanco Animal Health Incorporated (NYSE: ELAN). Under the terms of the transaction, Aratana shareholders will receive 0.1481 shares of Elanco common stock and a contingent value right representing $0.25 in cash for each Aratana share they own.
The Aratana merger investigation concerns whether the Board of Aratana breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Elanco Animal Health Incorporated is underpaying for Aratana shares, thus unlawfully harming Aratana shareholders.
To receive more information, please fill out the form.